Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Sharfman

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trialRobert L Ferris, William C Spanos, Rom Leidner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Melanoma Research|November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Cancer Discovery|December 30, 2016
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Kellie N Smith, Patrick M Forde, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Cancer Cell|September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell|December 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trialRobert L Ferris, William C Spanos, Rom Leidner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Melanoma Research|November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Cancer Discovery|December 30, 2016
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Kellie N Smith, Patrick M Forde, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Cancer Cell|September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell|December 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Pageof 2